Literature DB >> 24357233

[Potential and limitations of modern embolization therapy].

W A Wohlgemuth1, P Ostertag, W Uller.   

Abstract

Correct clinical and angiographic classification of vascular anomalies, including consideration of their flow pattern (high-flow versus low-flow), is the basis of accurate indications for minimally invasive therapy modalities such as embolization. Technical advancements and miniaturization of catheter materials (including steerable microwires, flow-directed microcatheters and detachable tips) gained access for embolotherapy to lesions anywhere in the body. The aim of embolization, which is mainly indicated for therapy of high-flow arteriovenous malformations, is the complete, permanent occlusion of the lesion nidus. Nowadays, embolotherapy is performed using permanent liquid embolization agents, in multiple staged sessions. This technique reduces complications such as ischemic necrosis and peripheral nerve lesions compared to alcohol embolization. Sole occlusion of the arterial inflow by surgical resection or interventional coil application is considered obsolete. The size of the lesion and the high treatment costs limit the use of embolotherapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24357233     DOI: 10.1007/s00106-013-2796-y

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  9 in total

1.  Early presentation of an extremity arteriovenous malformation.

Authors:  Jill B Webb; Mary O'Brien; Philip R John; Hiroshi Nishikawa
Journal:  Br J Plast Surg       Date:  2004-12

2.  Arteriovenous malformations of the body and extremities: analysis of therapeutic outcomes and approaches according to a modified angiographic classification.

Authors:  Sung Ki Cho; Young Soo Do; Sung Wook Shin; Dong-Ik Kim; Young Wook Kim; Kwang Bo Park; Eun Jin Kim; Hyun Joo Ahn; Sung Wook Choo; In-Wook Choo
Journal:  J Endovasc Ther       Date:  2006-08       Impact factor: 3.487

3.  Ethanol embolization of arteriovenous malformations: interim results.

Authors:  Young Soo Do; Wayne F Yakes; Sung Wook Shin; Byung-Boong Lee; Dong-Ik Kim; Wei Chiang Liu; Byung Seop Shin; Duk-Kyung Kim; Sung Wook Choo; In-Wook Choo
Journal:  Radiology       Date:  2005-05       Impact factor: 11.105

Review 4.  Updated classification of hemangiomas and other vascular anomalies.

Authors:  Mary Wu Chang
Journal:  Lymphat Res Biol       Date:  2003       Impact factor: 2.589

5.  Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics.

Authors:  J B Mulliken; J Glowacki
Journal:  Plast Reconstr Surg       Date:  1982-03       Impact factor: 4.730

6.  Nonadhesive liquid embolic agent for cerebral arteriovenous malformations: preliminary histopathological studies in swine rete mirabile.

Authors:  Y Murayama; F Viñuela; A Ulhoa; Y Akiba; G R Duckwiler; Y P Gobin; H V Vinters; R J Greff
Journal:  Neurosurgery       Date:  1998-11       Impact factor: 4.654

7.  Endovascular treatment of brain arteriovenous malformations using onyx: results of a prospective, multicenter study.

Authors:  L Pierot; A-C Januel; D Herbreteau; X Barreau; J Drouineau; J Berge; N Sourour; C Cognard
Journal:  J Neuroradiol       Date:  2009-02-14       Impact factor: 3.447

8.  Usefulness of percutaneously injected ethylene-vinyl alcohol copolymer in conjunction with standard endovascular embolization techniques for preoperative devascularization of hypervascular head and neck tumors: technique, initial experience, and correlation with surgical observations.

Authors:  J J Gemmete; N Chaudhary; A Pandey; D Gandhi; S E Sullivan; L J Marentette; D B Chepeha; S A Ansari
Journal:  AJNR Am J Neuroradiol       Date:  2009-12-24       Impact factor: 3.825

9.  Peripheral arteriovenous malformations with a dominant outflow vein: results of ethanol embolization.

Authors:  Sung Ki Cho; Young Soo Do; Dong Ik Kim; Young Wook Kim; Sung Wook Shin; Kwang Bo Park; Justin Sang Ko; Ae Ryoung Lee; Sung Wook Choo; In Wook Choo
Journal:  Korean J Radiol       Date:  2008 May-Jun       Impact factor: 3.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.